Myopathy due to epsilon amino-caproic acid

Related Experiment Video

Updated: Aug 17, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

C Kennard, M Swash, R A Henson

    Muscle & Nerve
    |May 1, 1980
    PubMed

    Insights

    Epsilon amino-caproic acid (EACA) treatment for subarachnoid hemorrhage caused a patient to develop necrotizing myopathy, potentially due to capillary damage. However, EACA-induced myopathy could not be replicated in rats.

    Area of Science:

    • Neurology
    • Toxicology
    • Pathology

    Background:

    • Subarachnoid hemorrhage necessitates treatment with antifibrinolytic agents like epsilon amino-caproic acid (EACA).
    • Muscle damage is a potential, though rarely reported, adverse effect of EACA therapy.

    Observation:

    • A patient undergoing EACA treatment for subarachnoid hemorrhage presented with subacute necrotizing myopathy.
    • Muscle biopsy revealed evidence of muscle fiber necrosis, with pathological features suggestive of capillary damage.

    Findings:

    • The observed myopathy in the patient was potentially linked to EACA administration.
    • Experimental induction of EACA myopathy in rats was unsuccessful, failing to reproduce the observed muscle pathology.

    Implications:

    • This case highlights a potential iatrogenic cause of myopathy associated with epsilon amino-caproic acid.
    • Further research is needed to elucidate the mechanism of EACA-induced myopathy and its relevance in clinical practice.
    • The differential diagnosis of myopathy in patients treated with EACA should include drug-induced capillary damage.

    More Related Videos

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration06:35

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

    Published on: June 15, 2018

    Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons07:43

    Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

    Published on: January 7, 2019

    Related Concept Videos

    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Myasthenia Gravis: Diagnostic Tests01:15

    Myasthenia Gravis: Diagnostic Tests

    Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
    The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
    Overview of Protein Metabolism01:21

    Overview of Protein Metabolism

    Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
    Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
    Inborn Errors of Metabolism01:20

    Inborn Errors of Metabolism

    Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
    Botulism01:22

    Botulism

    Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
    Myasthenia Gravis ll: Pathophysiology01:22

    Myasthenia Gravis ll: Pathophysiology

    The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...